Vertex presents new data across portfolio of cystic fibrosis medicines including alyftrek® at the north american cystic fibrosis conference

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced the presentation of multiple abstracts demonstrating the clinical benefits of treatment with cftr modulators, including the company's most recently approved medicine, alyftrek® (vanzacaftor/tezacaftor/deutivacaftor), at the north american cystic fibrosis conference (nacfc) held from october 22-25 in seattle, washington. several of the abstracts that will be presented at this year's conference demonstrate.
VRTX Ratings Summary
VRTX Quant Ranking